יחס חוב כולל להון עצמי bioAffinity Technologies (BIAF)

This daily price chart illustrating the debt-to-equity trends for bioAffinity Technologies (BIAF) demonstrates the 0.38 metric. The business is based on the promotion of CyPath Lung non-invasive diagnostics for lung tumor detection via the B2B segment. The project's success relies on FDA approval and the implementation of sputum analysis in clinics. Meanwhile, bioAffinity Technologies (BIAF) adheres to medical protocols regarding chemical disposal and energy efficiency.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to shareholders' equity, determining the financial stability and the degree of a company's dependence on external creditors. By analyzing changes in the total debt-to-equity level, one can assess the extent to which the bioAffinity Technologies (BIAF) research-driven model—characterized by high R&D expenditures and talent retention—relies on internal resources, confirming a conservative approach to financing.